<PAGE> 1

              SECURITIES AND EXCHANGE COMMISSION

                    Washington, D.C.  20549

                           FORM 10-Q



(Mark One)

[ X ]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
          SECURITIES EXCHANGE ACT OF 1934

          For the quarterly period ended June 30, 2000

                              OR

[    ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
          SECURITIES EXCHANGE ACT OF 1934

          For the transition period from_______________to_______________

          Commission file number 0-12992

                                SYNTHETECH, INC.
             (Exact name of registrant as specified in its charter)

                     Oregon                       84-0845771
               (State or Other Jurisdiction       (I.R.S. Employer
             of Incorporation or Organization)    Identification No.)

             1290 Industrial Way, Albany, Oregon         97321
           (Address of Principal Executive Offices)     (Zip Code)

                               (541) 967-6575
               (Registrant's Telephone Number, Including Area Code)

      Indicate by check mark whether the registrant:  (1)  has
filed  all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12
months  (or  for  such shorter period that the registrant  was
required  to file such reports), and (2) has been  subject  to
such filing requirements for the past 90 days.

Yes  X    No_____

      The  number of shares of the registrant's common  stock,
$.001  par  value,  outstanding  as  of  August  9,  2000  was
14,276,641.

<PAGE> 2




                          PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

<TABLE>
<CAPTION>
<S>                                         <C>               <C>

                               SYNTHETECH, INC.

                                BALANCE SHEETS
                            -------------------------

                                             (unaudited)
                                               June 30,           March 31,
                                                 2000               2000
---------------------                         -----------        -----------

 ASSETS
 ------

CURRENT ASSETS:
  Cash and cash equivalents                  $  7,362,000       $  6,404,000
  Accounts receivable, less allowance
    for doubtful accounts of $15,000
    for both periods                            1,800,000          2,433,000
  Income tax receivable                             2,000            137,000
  Inventories                                   4,112,000          4,112,000
  Prepaid expenses                                280,000            285,000
  Deferred income taxes                           140,000            140,000
  Other current assets                              8,000             31,000
                                              ------------       -----------
    TOTAL CURRENT ASSETS                       13,704,000         13,542,000


PROPERTY, PLANT AND EQUIPMENT, at cost, net    12,983,000         13,375,000
                                              -----------        -----------
    TOTAL ASSETS                              $26,687,000        $26,917,000
                                              ===========        ===========

The accompanying notes are an integral part of these financial statements.
</TABLE>
<PAGE> 3
<TABLE>
<CAPTION>
<S>                                             <C>            <C>

                               SYNTHETECH, INC.

                                BALANCE SHEETS
                           -------------------------
                                  (continued)

                                                 (unaudited)
                                                   June 30,       March 31,
                                                     2000           2000
--------------------------------------            -----------    -----------
  LIABILITIES AND SHAREHOLDERS' EQUITY
--------------------------------------

CURRENT LIABILITIES:
  Current portion of note payable                  $    15,000    $    17,000
  Accounts payable                                     263,000        547,000
  Accrued compensation                                 114,000        109,000
  Deferred revenue                                     294,000        544,000
  Other accrued liabilities                             15,000         25,000
                                                   -----------    -----------
    TOTAL CURRENT LIABILITIES                          701,000      1,242,000

DEFERRED INCOME TAXES                                  482,000        482,000

NOTE PAYABLE, net of current portion                   132,000        135,000

SHAREHOLDERS' EQUITY:
  Common stock, $.001 par value; authorized
   100,000,000 shares; issued and outstanding,
   14,277,000 shares for both periods                   14,000         14,000
  Paid-in capital                                    8,784,000      8,793,000
  Deferred  compensation                               (26,000)       (40,000)
  Retained earnings                                 16,600,000     16,291,000
                                                   -----------    -----------
    TOTAL SHAREHOLDERS' EQUITY                      25,372,000     25,058,000
                                                   -----------    -----------
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY     $26,687,000    $26,917,000
                                                   ===========    ===========

The accompanying notes are an integral part of these financial statements.
</TABLE>

<PAGE>4
<TABLE>
<CAPTION>
<S>                                               <C>             <C>

                                SYNTHETECH, INC.

                              STATEMENTS OF INCOME
                              --------------------
                                  (unaudited)


For The Three Month Period Ended June 30,          2000             1999
-----------------------------------------        ---------        ---------

REVENUES                                       $ 2,698,000       $ 4,636,000
COST OF SALES                                    1,737,000         2,629,000
                                               -----------       -----------
GROSS PROFIT                                       961,000         2,007,000

  Research and development                          95,000           127,000
  Selling, general and administrative              357,000           343,000
                                               -----------       -----------
OPERATING EXPENSE                                  452,000           470,000
                                               -----------       -----------
OPERATING INCOME                                   509,000         1,537,000

OTHER INCOME (LOSS), net                            (8,000)           87,000
INTEREST EXPENSE                                    (3,000)           (3,000)
                                               -----------       -----------
INCOME BEFORE INCOME TAXES                         498,000         1,621,000

PROVISION FOR INCOME TAXES                         189,000           616,000
                                               -----------       -----------
NET INCOME                                     $   309,000       $ 1,005,000
                                               ===========       ===========


BASIC EARNINGS PER SHARE                             $0.02             $0.07
                                                     =====             =====

DILUTED EARNINGS PER SHARE                           $0.02             $0.07
                                                     =====             =====

The accompanying notes are an integral part of these financial statements.
</TABLE>

<PAGE> 5
<TABLE>
<CAPTION>
<S>                                                <C>            <C>

                               SYNTHETECH, INC.

                           STATEMENTS OF CASH FLOWS
                           ------------------------
                                (unaudited)

For The Three Month Period Ended June 30,                  2000         1999
-----------------------------------------                 ------       ------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                           $   309,000  $ 1,005,000
Adjustments to reconcile net income to
  net cash provided by operating activities:
    Depreciation, amortization and other                 714,000      386,000
    Amortization of deferred compensation                  5,000       13,000
  Proceeds from stock option exercises and
    disqualifying dispositions                                 -        7,000

    (Increase) decrease in assets:
      Accounts receivable, net                           633,000      944,000
      Inventories                                              -      (17,000)
      Prepaid expenses                                     5,000       (3,000)
      Income tax receivable                              135,000            -
      Other assets                                        23,000      (12,000)

    Increase (decrease) in liabilities:
      Accounts payable and accrued liabilities          (289,000)  (1,218,000)
      Deferred revenue                                  (250,000)           -
                                                     -----------  -----------
        Net cash provided by operating activities      1,285,000    1,105,000
                                                     -----------  -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
   Property, plant and equipment purchases, net         (322,000)    (835,000)
                                                     -----------  -----------
        Net cash used in investing activities           (322,000)    (835,000)
                                                     -----------  -----------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Principal payments under long-term debt
    obligations                                           (5,000)      (4,000)
                                                     -----------  -----------
        Net cash provided by (used in) financing
          activities                                      (5,000)      (4,000)
                                                     -----------  -----------
NET INCREASE IN CASH AND CASH EQUIVALENTS                958,000      266,000

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD       6,404,000     7,470,000
                                                     -----------   -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD           $ 7,362,000   $ 7,736,000
                                                     ===========   ===========
NON-CASH INVESTING ACTIVITIES:
Issuance of stock options at below fair value        $   (9,000)   $     4,000

The accompanying notes are an integral part of these financial statements.
</TABLE>

<PAGE> 6

                 NOTES TO FINANCIAL STATEMENTS


NOTE A.   GENERAL AND BUSINESS


The  summary  financial statements included herein  have  been
prepared, without audit, pursuant to the rules and regulations
of   the   Securities   and  Exchange   Commission.    Certain
information  and  footnote disclosures  normally  included  in
financial  statements  prepared in accordance  with  generally
accepted accounting principles have been condensed or  omitted
pursuant  to  such rules and regulations, although  Synthetech
management believes that the disclosures are adequate to  make
the  information  presented not misleading.  It  is  suggested
that these summary financial statements be read in conjunction
with  the  financial statements and the notes thereto included
in Synthetech's fiscal 2000 Form 10-K.

  Interim  financial  statements  are  by  necessity  somewhat
tentative;  judgments are used to estimate  quarterly  amounts
for  items  that are normally determinable only on  an  annual
basis.  For example, provision for income taxes is an estimate
of  the  annual liability pro-rated over the quarters  of  the
fiscal year based on estimates of annual income.  Further, all
inventory  quantities are verified by physically counting  the
units  on  hand  at  least  once a year.   Normally,  selected
inventory  items are cycle counted during each  quarter.   For
those  inventories not counted during the quarter,  quantities
are  determined using measured sales and production  data  for
the period.

The  interim  period information included herein reflects  all
adjustments   which   are,  in  the  opinion   of   Synthetech
management, necessary for a fair statement of the  results  of
the  respective  interim periods.  Results of  operations  for
interim  periods are not necessarily indicative of results  to
be expected for an entire year.



NOTE B.   STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
<S>                          <C>           <C>
          Supplemental cash flow disclosures for the three
month period ended June 30:

          Cash Paid
          ---------
                                2000             1999
                                ----             ----
      Income Taxes          $  54,000        $ 490,000
      Interest              $   3,000        $   4,000

</TABLE>

<PAGE> 7




           NOTES TO FINANCIAL STATEMENTS (continued)

NOTE C. EARNINGS PER SHARE

Basic  earnings per share (EPS) are computed by  dividing  net
income  by  the  weighted average number of shares  of  common
stock  outstanding  during the period.  Diluted  earnings  per
share  are  computed by dividing net income  by  the  weighted
average  number  of shares of common stock  and  common  stock
equivalents  outstanding during the period,  calculated  using
the  treasury  stock method as defined in SFAS No.  128.   The
following  is a reconciliation of the shares used to calculate
basic earnings per share and diluted earnings per share:

<TABLE>
<CAPTION>
<S>                                         <C>         <C>

      For The Three Months Ended June 30,      2000        1999
      -----------------------------------      ----        ----

     Weighted average shares
      outstanding for basic EPS             14,276,641   14,252,108

     Dilutive effect of common
      stock options issuable
      under treasury stock method               24,970       67,494
                                            ----------   ----------
     Weighted average common and
      common equivalent shares
      outstanding for diluted EPS           14,301,611   14,319,602
                                            ==========   ==========
</TABLE>

The  following common stock equivalents were excluded from the
earnings per share computation because their effect would have
been anti-dilutive:

<TABLE>
<CAPTION>
<S>                                          <C>         <C>

      For The Three Months Ended June 30,       2000        1999
      -----------------------------------       ----        ----
     Common stock options outstanding         764,875      523,800

</TABLE>

<PAGE> 8
           NOTES TO FINANCIAL STATEMENTS (continued)


NEW ACCOUNTING PRONOUNCEMENT

In   June   1999,  the  FASB  issued  Statement  of  Financial
Accounting  Standards  No.  137,  "Accounting  for  Derivative
Instruments and Hedging Activities" ("SFAS 137").  SFAS 137 is
an  amendment  to Statement of Financial Accounting  Standards
No.  133,  "Accounting for Derivative Instruments and  Hedging
Activities."   SFAS 137 establishes accounting  and  reporting
standards  for  all  derivative  instruments.   SFAS  137   is
effective for fiscal years beginning after June 15, 2000.  The
Company  does  not  currently have any derivative  instruments
and, accordingly, does not expect the adoption of SFAS 137  to
have  an  impact  on  its  financial position  or  results  of
operations.

<PAGE> 9

Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations


RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, the
percentage  of revenues represented by each item  included  in
the Statements of Income.

<TABLE>
<CAPTION>
<S>                                    <C>              <C>

                          Percentage of Revenues
                          ----------------------

For The Three Month Period Ended June 30,         2000       1999
-----------------------------------------         ----       ----

Revenues                                         100.0 %    100.0 %
Cost of Sales                                     64.4       56.7
                                                 -------    -------
Gross Profit                                      35.6       43.3

  Research and development                         3.5        2.7
  Selling, general and administration             13.2        7.4
                                                 -------    -------
Operating Expense                                 16.7       10.1
                                                 -------    -------
Operating Income                                  18.9       33.2

Other Income (Loss), net                          (0.3)       1.9
Interest Expense                                  (0.1)      (0.1)
                                                 -------    -------
Income Before Income Taxes                        18.5       35.0

Provision For Income Taxes                         7.0       13.3
                                                 -------    -------
Net Income                                        11.5 %     21.7 %
                                                 =======    =======

</TABLE>

Revenues
--------
Revenues  decreased  by  42% to $2.70  million  in  the  first
quarter of fiscal 2001 from $4.64 million in the first quarter
of  fiscal 2000.  International sales in the first quarter  of
fiscal  2001 were $328,000, compared to $3.00 million  in  the
first  quarter  of fiscal 2000 representing an  89%  decrease.
International sales, like all Company revenues, are subject to
significant  quarterly fluctuations.  These sales were  mainly
to  Europe  in the first quarter of fiscal 2001 and mainly  to
Europe and Mexico for the comparable quarter of fiscal 2000.

<PAGE> 10


Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)


The  decrease in revenues for the first quarter of fiscal 2001
from the first quarter of fiscal 2000 reflected the absence of
revenue from large-scale orders and the unpredictable ordering
cycles  inherent  in drug development projects.   The  Company
expects  that these dynamics, which also affected Synthetech's
results  during the second half of fiscal 2000, will  continue
in  the  second quarter of fiscal 2001 causing the first  half
results for fiscal 2001 to be similar to those for the  second
half  of  fiscal 2000.  Looking beyond the second  quarter  of
fiscal  2001,  the industry environment in which  the  Company
operates  makes  it  difficult to predict with  certainty  the
level of future business.  The Company, however, continues  to
be  a  supplier of Peptide Building Blocks (PBBs) for  several
pharmaceutical development projects advancing through clinical
trials  and  these  projects  could  have  substantial  future
business   potential.   There  are,  however,   many   factors
affecting  the success of these drug projects and Synthetech's
involvement.  (See "Industry Factors" below.)

The  Company's strong balance sheet has allowed it to  weather
the  current  downturn without hindering  long-term  strategic
direction.   Synthetech continues to invest in  the  necessary
infrastructure and organizational resources.  (See  "Liquidity
and Capital Resources" below.)


Gross Profit
------------
Gross  profit  was $961,000 or 36% of revenues  in  the  first
quarter of fiscal 2001 as compared to $2.01 million or 43%  of
revenues in the first quarter of fiscal 2000.  The decrease in
gross  profit  margin  for the first quarter  of  fiscal  2001
primarily  reflected the downward pressure caused by  a  lower
level  of  revenues  and the increased manufacturing  overhead
costs  associated with the second phase expansion of  the  new
plant.

Operating Expenses
------------------
Research and development (R&D) expense decreased to $95,000 in
the  first  quarter of fiscal 2001 from $127,000 in the  first
quarter  of  fiscal 2000.  As a percentage  of  revenues,  the
first  quarter of fiscal 2001 was 4% compared to  3%  for  the
first  quarter  of fiscal 2000.  The decrease in  R&D  expense
primarily  reflected reduced costs related to the  acquisition
of  staff  and  reduced compensation expenses related  to  the
granting  of  a non-qualified stock option.  Selling,  general
and  administrative (SG&A) expense was $357,000 in  the  first
quarter  of  fiscal  2001 compared to $343,000  in  the  first
quarter  of  fiscal  2000, or 13% and 7% as  a  percentage  of
revenues, respectively.  Operating expenses as a percentage of
revenues were approximately 17% in the first quarter of fiscal
2001 and 10% in the first quarter of fiscal 2000.

Operating Income
----------------
Operating income decreased to $509,000 in the first quarter of
fiscal  2001 compared with $1.54 million in the first  quarter
of  fiscal 2000.  As a percent of revenues, the first  quarter
of  fiscal  2001 was 19% compared to 33% of revenues  for  the
same period of fiscal 2000.

<PAGE> 11

Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)

Other Income (Loss)
-------------------
The  net  other loss of $8,000 in the first quarter of  fiscal
2001  included  $99,000  in  interest  earnings  offset  by  a
$107,000 equipment write down.  The $87,000 of income  in  the
first  quarter  of  fiscal 2000 primarily  reflected  interest
earnings.

Net Income
----------
For  the  first  quarter  of fiscal 2001  the  Company  earned
$498,000 before income taxes.  A provision for income taxes of
$189,000  resulted in net income of $309,000.  For  the  first
quarter of fiscal 2000 the Company earned $1.62 million before
income  taxes.   A  provision for  income  taxes  of  $616,000
resulted  in  net  income  of $1.01  million.   The  Company's
effective  tax  rate was 38% for the first quarter  of  fiscal
2001 and the first quarter of fiscal 2000.



INDUSTRY FACTORS

The  market for PBBs is driven by the market for synthetically
manufactured peptide, peptidomimetic small molecule and  other
drugs  in  which  they are incorporated. The drug  development
process  for these drugs is dictated by the marketplace,  drug
companies and the regulatory environment. The Company  has  no
control over the pace of these drug development efforts, which
drugs  get  selected  for  clinical trials,  which  drugs  are
approved by the FDA and, even if approved, the ultimate market
potential of such drugs.

The three stages of the drug development process include:  R&D
or  discovery  stage, clinical trial stage and  marketed  drug
stage. Synthetech's customers can spend years researching  and
developing  new  drugs,  taking only  a  small  percentage  to
clinical  trials  and  fewer  yet  to  commercial  market.   A
substantial amount of the activity continues to occur  at  the
earlier  stages  of  research  and  development  and  clinical
trials.  The  market  for  peptide  and  peptidomimetic  small
molecule drugs is still very early in development.

Recurring  sales of PBBs for development programs is  sporadic
at  best.  The  high  cancellation rate for  drug  development
programs  results in a significant likelihood that there  will
be  no  subsequent or "follow-on" PBB sales for any particular
drug development program. Accordingly, the level of purchasing
by  the  Company's  customers for  specific  drug  development
programs varies substantially from quarter to quarter and  the
Company  cannot rely on any one customer as a constant  source
of revenue.

The  size  of  the  PBB  orders  for  marketed  drugs  can  be
substantially larger than those for the discovery or  clinical
trial  stages.  Sales  of  PBBs for marketed  drugs  can  also
provide an opportunity for continuing longer-term sales. While
not  subject  to  the  same high cancellation  rate  faced  by
discovery  and clinical trial stage drug development programs,
the demand for the approved drugs, however, remains subject to
many  uncertainties, including, without limitation,  the  drug
price,  the  drug  side  effects and the  existence  of  other
competing   drugs.  These  factors,

<PAGE> 12

Item   2.    Management's Discussion and Analysis of Financial
Condition and Results  of Operations (continued)

which  are outside of the control of the Company, will  affect
the  level  of demand for the drug itself and, therefore,  the
demand  for  PBBs.  Also, industry cost  pressures  can  cause
pharmaceutical companies to explore and, as was the case  with
one  of  the  large-scale orders, ultimately adopt alternative
manufacturing  processes which do not  include  the  Company's
PBBs as an intermediate. Finally, with the longer-term, larger-
scale  orders,  the Company expects increased  competition  to
supply these PBBs.

Accordingly,  these industry factors create an  inability  for
the  Company to predict future demand beyond its current order
base.  Until the Company develops a stable baseload of demand,
the  Company  is likely to continue to experience  significant
fluctuations in its quarterly results.



LIQUIDITY AND CAPITAL RESOURCES

At  June  30, 2000, the Company had working capital of  $13.00
million  compared to $12.30 million at March  31,  2000.   The
Company's  cash and cash equivalents at June 30, 2000  totaled
$7.36  million.   The  Company does not invest  in  derivative
securities.   In  addition,  the  Company  had  a  $1  million
unsecured  bank line of credit of which there  was  no  amount
outstanding at June 30, 2000.

The  decrease in accounts receivable to $1.80 million at  June
30,  2000  from $2.43 million at March 31, 2000 reflected  the
timing  of shipments and collections during the quarter.   The
decrease  in income tax receivable to $2,000 at June 30,  2000
from $137,000 at March 31, 2000 reflected the increase in  tax
liability  for the quarter.  The decrease in accounts  payable
to  $263,000 at June 30, 2000 from $547,000 at March 31,  2000
primarily  reflected the reduction of expenditure  commitments
related to the second phase of the plant expansion and  timing
of  raw  material purchases.  The decrease in deferred revenue
to  $294,000 at June 30, 2000 from $544,000 at March 31,  2000
resulted  from  the recognition of revenue associated  with  a
$250,000 customer advance payment.

The Company had approximately $322,000 of capital expenditures
during  the  first  quarter  of  fiscal  2001  which  included
$127,000  for equipment and equipment upgrades in the existing
plant  and  $195,000 for the second-phase  of  the  new  plant
expansion.   The  Company  anticipates  fiscal  2001   capital
expenditures for the existing plant and the completion of  the
second-phase  of  the new plant expansion to be  $700,000  and
$300,000,  respectively.   The  Company  is  also  considering
investing   roughly   $2.25  million  in  on-site   wastewater
treatment capabilities and in an upgrade to the R&D labs.  The
Company  expects  to  finance all  capital  expenditures  from
internal  cash flow and does not anticipate the need  for  any
new debt or equity financing.


                 _____________________________

<PAGE> 13

This  Form  10-Q  includes "forward-looking"  information  (as
defined  in  Section 27A of the Securities  Act  of  1933  and
Section   21E  of  the  Securities  Exchange  Act  of   1934).
Investors   are  cautioned  that  forward-looking   statements
involve  risks  and uncertainties, and various  factors  could
cause  actual results to differ materially from those  in  the
forward-looking   statements.    Forward-looking    statements
include,  without limitation, any statement that may  predict,
forecast,  indicate  or imply future results,  performance  or
achievements,   and   may   contain   the   words   "believe,"
"anticipate,"  "expect,"  "estimate,"  "project,"  "will  be,"
"will continue," "will likely result," or words or phrases  of
similar  meanings.  The risks and uncertainties  include,  but
are  not limited to, the following:  the uncertain market  for
products, customer concentration, potential quarterly  revenue
fluctuations,  industry cost factors, competition,  government
regulation,  product  liability risks,  technological  change,
increased   costs  associated  with  the  Company's   facility
expansions,  international  business  risks,  and  Y2K  risks.
Investors  are  directed  to the Company's  filings  with  the
Securities  and Exchange Commission, including  the  Company's
Form 10-K for the fiscal year ended March 31, 2000, which  are
available  from  the  Company without charge,  for  a  further
description of the risks and uncertainties related to forward-
looking  statements made by the Company as well  as  to  other
aspects of the Company's business.

<PAGE> 14

PART II - OTHER INFORMATION



Item 6.  Exhibits and Reports on Form 8-K

(a)  Exhibits

       3(i)*   Articles of Incorporation of Synthetech, Inc., as amended.

       3(ii)   Bylaws of Synthetech, Inc., as amended.

      27       Financial Data Schedule
__________________
      *  Incorporated by reference herein from the Company's
          Form 10-KSB for the year ended March 31, 1997.


(b)  Reports
     No reports on Form 8-K were filed during the quarter.

<PAGE> 15

                          SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of
1934,  the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.






                                        SYNTHETECH, INC.
                                         (Registrant)



Date:    August 10, 2000              /s/ M. Sreenivasan
                                          M. Sreenivasan
                                          President & C.E.O.



Date:    August 10, 2000              /s/ Charles B. Williams
                                          Charles B. Williams
                                          Vice President, Finance
                                          and  Administration, C.F.O.,
                                          Chief Accounting Officer




<PAGE>
                          INDEX TO EXHIBITS

                                                           Sequential Page No.

      3(ii)  Bylaws of Synthetech, Inc., as amended.

     27      Financial Data Schedule for the Three Months
             Ended June 30, 2000